Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

February 26, 2018

DLSS showcases rare disease patient support model to improve therapy adherence

Dohmen Life Science Services (DLSS) experts arrived in Philadelphia, Pa. today for the upcoming Hub and SPP Model Optimization conference hosted by CBI. The DLSS team joins more than 700 leaders in patient access, reimbursement and specialty distribution who are taking a closer look at the ever-evolving needs of orphan drug manufacturers and their patients.

“The market is getting more complex by the day, but one thing is certain - rare disease patients deserve robust services and support to stay adherent and create better health outcomes,” said Kathi Henson, DLSS Chief Patient Services Officer. “We’ve got to push ourselves to think beyond traditional business models and consider what our clients and their patients really need.”

Henson will join Joff Mosukawa, president, Diligentia, and Mary Pierce, a rare disease patient and advocate, to discuss an integrated Hub and specialty pharmacy outsourcing model that may improve onboarding, patient support, data collection and analysis to benefit both the manufacturer and the patients they serve. Pierce will share her personal experiences and insights into the driving factors behind patient satisfaction and ongoing therapy compliance.

Visit CBI’s Hub and SPP Model Optimization website for a complete look at the agenda.